ABATACEPT (ORENCIA)

Course overview

Abatacept is U.S. FDA-approved to treat moderate/severe rheumatoid arthritis (RA) in adults as monotherapy or with other disease-modifying antirheumatic drugs (DMARDs), and moderate/severe active polyarticular juvenile idiopathic arthritis (JIA) in patients ≥ 6 years as monotherapy or with methotrexate. This continuing education module is designed to give the reader/learner an increased understanding of abatacept. Readers may explore any or all of the topics. One contact hour of continuing education credit is available for those who successfully complete the post-test and evaluation form.